CONGRESSES
CONGRESSES
Find information on previous and upcoming congresses
View upcoming congresses and filter through abstracts, presentations, and posters from past congresses.
Upcoming congresses
American Academy of Asthma, Allergy and Immunology (AAAAI)
BioCryst will attend the 2026 American Academy of Asthma, Allergy and Immunology (AAAAI) from Feb 27 – Mar 2, 2026.
Browse our archive of congress materials
Filter
Showing 122 Materials
-
Oral Berotralstat Reduces Hereditary Angioedema Attack Rates in Pediatric Patients Aged 2 to <12 Years Without Long-Term Prophylaxis During the 12-Week Standard of Care Period: Interim Data from the APeX-P Study
WSAAI | 2026 | HAE -
Results from the ALPHA-STAR Trial, a Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Navenibart in Participants with Hereditary Angioedema (HAE)
HAEi EMEA | 2025 | HAE -
Long-term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema (HAE): Initial Combined Results from ALPHA-STAR and ALPHA-SOLAR
HAEA National Summit | 2025 | HAE -
Treatment with Navenibart (STAR-0215) Reduces Attack Severity and Use of Rescue Medication in Patients with Hereditary Angioedema (HAE): Interim Results from the ALPHA-STAR Trial
HAEA National Summit | 2025 | HAE -
ALPHA-ORBIT -A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Participants with Hereditary Angioedema (HAE)
HAEA National Summit | 2025 | HAE -
Treatment with Navenibart (STAR-0215) Reduces Attack Severity and Use of Rescue Medication in Patients with Hereditary Angioedema (HAE): Interim Results from the ALPHA-STAR Trial
EAC | 2025 | HAE -
Long-term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema (HAE): Initial Combined Results from ALPHA-STAR and ALPHA-SOLAR
EAACI | 2025 | HAE -
Results from the ALPHA-STAR Trial, a Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Navenibart (STAR-0215) in Participants with HAE
EAACI | 2025 | HAE -
ALPHA-ORBIT – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Participants with Hereditary Angioedema (HAE)
EAACI | 2025 | HAE -
ALPHA-ORBIT -A Phase 3 clinical trial to evaluate the efficacy and safety of navenibart in participants with hereditary angioedema (HAE)
CSACI | 2025 | HAE